查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984221

抗发炎治疗市场：2026-2032年全球市场预测（依治疗分类、作用机制、给药途径、适应症、通路及最终用户划分）

Anti-Inflammatory Therapeutics Market by Therapeutic Class, Mechanism Of Action, Route Of Administration, Indication, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，抗发炎药物市场价值将达到 221.6 亿美元，到 2026 年将成长至 231.9 亿美元，到 2032 年将达到 338.5 亿美元，复合年增长率为 6.23%。

主要市场统计数据
基准年 2025 221.6亿美元
预计年份：2026年 231.9亿美元
预测年份 2032 338.5亿美元
复合年增长率 (%) 6.23%

该分析整合了临床奖励、相关人员和决策者的策略重点，揭示了现代抗发炎疗法的现状。

发炎性疾病的治疗模式呈现出快速的科学进步、临床范式的转变以及日益复杂的商业性环境等特征。分子生物学和免疫学的进步拓展了临床医生可选择的治疗方案，而患者的期望和支付方的严格审查则凸显了相对安全性、长期疗效和真实世界疗效的重要性。本文奖励了当前发炎性疾病的治疗环境，整合了影响药物研发和商业化的临床因素、监管影响以及相关人员。

从科学突破、适应性监管途径和商业性压力三个方面，对治疗创新和获取的动态进行综合观点，从根本上改变治疗创新和获取的动态。

抗发炎领域的蓬勃发展得益于科学、监管和商业性领域诸多转折点的汇聚，这些转折点正在重塑治疗方法的发现、开发和应用方式。近年来，治疗策略已从广泛的免疫抑制转向针对特定发炎路径的调节，这重新定义了人们对疗效、安全性和长期疾病管理的预期。同时，监管路径也在不断发展，以适应新的治疗方法和适应性开发方法，促使申办方在专案设计的早期阶段就将监管策略纳入考量。

详细分析 2025 年美国关税调整将如何影响整个治疗领域产品组合的供应链韧性、製造策略和产品供应。

关税政策和贸易趋势将对医药原料和成品的供应及成本结构产生微妙但显着的影响。 2025年美国关税调整为供应链规划、筹资策略和国际采购决策引入了新的变数。製造商和经销商正在透过重新评估供应商所在地、选择替代製造地以及重新评估库存政策来应对这些变化，以维持供应的连续性并保护利润率结构。

基于全面细分的洞察，将治疗领域、作用机制、给药途径、分销管道、适应症和最终用户趋势与实际开发和商业化挑战联繫起来。

精细化的市场区隔观点揭示了不同治疗领域、作用机制、给药途径、分销管道、适应症和终端用户所面临的独特策略挑战，这些挑战在产品开发和商业化过程中都呈现出独特的机会和限制因素。按治疗领域划分，市场涵盖生物製药和糖皮质激素，以及缓解疾病抗风湿药、 Janus激酶抑製剂、非类固醇消炎剂和磷酸二酯酶抑制剂，每种药物在临床证据、生产复杂性和上市后安全性监测方面都提出了不同的要求。依作用机制划分，治疗方法靶向Cyclooxygenase通路、白细胞介素信号通路、 Janus激酶级联反应、磷酸二酯酶和肿瘤坏死因子（TNF），这种机制的多样性要求采用个体化的生物标誌物策略和差异化的临床终点。

针对美洲、欧洲、中东、非洲和亚太地区，协调监管多样性、偿还模式和基础设施现实的区域性策略考量。

区域趋势对监管合作、报销途径和商业性实施有显着影响，每个区域都有其独特的临床模式和业务重点。在美洲，医疗保健系统涵盖了从高度私有化模式到公共保险主导模式的各种类型，导致处方集、就医时间和患者支持计划要求等方面存在差异。该区域的临床实践模式和指南采纳情况会影响保险公司和医疗服务提供者对疗效比较的预期以及对证据标准的要求。

主要企业如何将科学差异化、策略联盟和生命週期策略结合，以优化其治疗产品线并向支付方证明其价值？

主要企业之间的竞争体现在科学差异化、策略伙伴关係和产品组合优化等。产业领导者优先考虑作用机制明确的实证标标靶治疗，并投资于生物製药和小分子药物，这些药物与传统的频谱药物相比，安全性更高，特异性更强。跨领域合作与授权授权十分普遍，各公司力求利用外部创新来补充自身能力，缩短临床试验週期，并降低后期研发风险。

为了确保产品顺利上市和持续获得治疗方法，高阶主管需要采取切实可行的、优先的行动，协调研发、生产、市场进入和商业化团队。

行业领导者应采取综合方法，使早期科学筛选与后续市场进入和商业性需求保持一致。这种方法应包括从计画设计的最初阶段就纳入支付方和卫生经济学的见解，确保临床试验终点和健康结果指标相关人员报销利害关係人而言可靠。同时，投资生产柔软性和地理多元化将确保供应连续性，并降低贸易中断带来的风险。

透过高度透明的调查方法，结合专家访谈、有针对性的二级文献综述和横断面分析，对临床、监管和营运方面检验。

本执行摘要的研究基础整合了定性访谈、有针对性的二手文献综述以及对监管和政策变化的结构化分析。访谈对象包括临床意见领袖、供应链主管、市场进入专家和治疗领域专家，涵盖了多方相关人员的观点。二级资讯来源包括同侪审查的临床文献、监管指导文件以及阐述机制特定证据和供应考虑的技术白皮书。

这个结论总结了治疗创新、证据一致性和实施在发炎性疾病治疗中如何全面决定长期成功和对患者的影响。

总之，精准的机制标靶化、适应性监管预期以及对可证实的实际疗效日益增长的需求，正在改变抗发炎疗法领域。这些因素为研发者、支付者和医疗服务提供者带来了机会和责任，促使他们在循证实践、供应链韧性以及以患者为中心的医疗模式方面开展合作。治疗差异化越来越需要分子设计、剂型和市场进入策略的协调一致，从而确保治疗方法的广泛应用和患者的永续效益。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：按治疗分类分類的抗发炎治疗药物市场

  • 生物製药
  • 皮质类固醇
  • 缓解疾病抗风湿药物
  • Janus激酶抑制剂
  • 非类固醇消炎剂
  • 磷酸二酯酶抑制剂

第九章：按作用机转分類的抗发炎药物市场

  • Cyclooxygenase抑制剂
  • 白细胞介素抑制剂
  • Janus激酶抑制剂
  • 磷酸二酯酶抑制剂
  • 肿瘤坏死因子抑制剂

第十章：抗发炎治疗药物市场：依给药途径划分

  • 口服
  • 肠外
    • 肌肉内部
    • 静脉
    • 皮下
  • 外用
    • 奶油
    • 凝胶
    • 软膏

第十一章：抗发炎治疗药物市场：依适应症划分

  • 气喘和呼吸系统疾病
  • 痛风
  • 发炎性肠道疾病
    • 克隆氏症
    • 溃疡性大肠炎
  • 骨关节炎
  • 银屑病
  • 类风湿性关节炎

第十二章：抗发炎治疗药物市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十三章：抗发炎治疗市场：依最终用户划分

  • 诊所
  • 居家照护
  • 医院
  • 专业医疗中心

第十四章：抗发炎治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 抗发炎治疗药物市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 抗发炎治疗药物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国抗发炎治疗药物市场

第十八章：中国抗发炎药市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC, Amgen Inc.
  • Bioventus
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Ferring Pharmaceuticals
  • Flexion Therapeutics, Inc
  • GlaxoSmithKline
  • Johnson & Johnson
  • La Roche AG
  • Merck & CO., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-5C6F41F5B03B

The Anti-Inflammatory Therapeutics Market was valued at USD 22.16 billion in 2025 and is projected to grow to USD 23.19 billion in 2026, with a CAGR of 6.23%, reaching USD 33.85 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 22.16 billion
Estimated Year [2026] USD 23.19 billion
Forecast Year [2032] USD 33.85 billion
CAGR (%) 6.23%

Framing the contemporary anti-inflammatory therapeutics landscape by synthesizing clinical innovation, stakeholder incentives, and strategic priorities for decision-makers

The therapeutic landscape for inflammatory disorders is characterized by rapid scientific progress, shifting clinical paradigms, and intensifying commercial complexity. Advances in molecular biology and immunology have expanded the toolbox available to clinicians, while patient expectations and payer scrutiny have elevated the importance of comparative safety, long-term outcomes, and real-world effectiveness. This introduction frames the current environment by synthesizing clinical drivers, regulatory influences, and stakeholder incentives that collectively shape development and commercialization pathways.

Translational breakthroughs have created opportunities across a spectrum of modalities, from targeted cytokine inhibitors to orally administered small molecules that modulate intracellular signaling. At the same time, traditional anti-inflammatory agents remain central to acute symptom control and perioperative management, reinforcing the need for integrated care models. By combining clinical insight with market-oriented perspectives, this section sets the groundwork for subsequent analysis, clarifying how therapeutic differentiation, delivery format, and distribution strategy influence adoption and lifecycle planning.

The objective of this executive summary is to present a balanced, evidence-informed narrative that supports strategic prioritization. It emphasizes where therapeutic innovation aligns with unmet clinical need, how shifting treatment paradigms affect stakeholder behavior, and what programmatic considerations should guide investment decisions. In short, the introduction is intended to orient readers to the principal forces shaping therapeutic development and access in the anti-inflammatory domain.

An integrated view of scientific breakthroughs, adaptive regulatory pathways, and commercial pressures that are fundamentally altering treatment innovation and access dynamics

Momentum in the anti-inflammatory space is driven by convergent scientific, regulatory, and commercial inflection points that are reshaping how therapies are discovered, developed, and adopted. Recent years have seen a pronounced pivot from broad immunosuppression toward targeted modulation of discrete inflammatory pathways, which has recalibrated expectations for efficacy, safety, and long-term disease control. Concurrently, regulatory pathways have evolved to accommodate novel modalities and adaptive development approaches, prompting sponsors to embed regulatory strategy early in program design.

Commercially, payers and health systems are leveraging real-world evidence and value-based contracting to distinguish treatments that demonstrate durable benefit and cost offsets. This pressure has encouraged manufacturers to align trial endpoints more closely with patient-centered outcomes and health economic measures. Additionally, technological innovations in drug delivery and telemedicine have broadened access pathways, enabling novel channel strategies and patient-centric support services that can influence adherence and persistence.

The cumulative effect is a more complex but opportunity-rich ecosystem in which therapeutic differentiation is multi-dimensional. Scientific advances permit more precise targeting of disease biology, regulatory adaptations encourage innovative development frameworks, and commercial stakeholders increasingly demand demonstrable value. As a result, organizations that integrate clinical evidence generation, payer engagement, and agile commercialization planning will be best positioned to navigate the evolving terrain.

A nuanced analysis of how 2025 United States tariff adjustments are influencing supply chain resilience, manufacturing strategy, and product availability across therapeutic portfolios

Tariff policies and trade dynamics can exert a subtle yet material influence on the availability and cost structure of pharmaceutical inputs and finished products. Changes to United States tariffs in 2025 have introduced new variables for supply chain planning, procurement strategy, and international sourcing decisions. Manufacturers and distributors have responded by reassessing supplier footprints, qualifying alternate manufacturing sites, and re-evaluating inventory policies to maintain continuity of supply and to protect margin structures.

These adjustments have been particularly relevant for parenteral products and biologics, where cold-chain logistics and contract manufacturing relationships are tightly integrated with production timelines. In some instances, firms have accelerated vertical integration or capacity investments to mitigate exposure to cross-border cost fluctuations. Concurrently, emphasis on nearshoring and regional manufacturing hubs has increased, as organizations seek to reduce geopolitical risk and to shorten lead times for critical therapeutic agents.

Beyond manufacturing, payers and health systems may see indirect effects as procurement practices adapt to changed cost bases. Providers are reassessing formularies and group purchasing arrangements to preserve affordability while ensuring clinical adequacy. Overall, the tariff landscape underscores the importance of resilient supply chains, scenario-based financial modeling, and proactive stakeholder communication to sustain product availability and to preserve patient access.

Comprehensive segmentation-driven insights that map therapeutic class, mechanism, delivery, channels, indications, and end-user dynamics to practical development and commercialization imperatives

A granular segmentation lens reveals distinct strategic imperatives across therapeutic class, mechanism of action, route of administration, distribution channel, indication, and end user, each presenting unique opportunities and constraints for product development and commercialization. Based on Therapeutic Class, the market spans Biologics and Corticosteroids as well as Disease Modifying Antirheumatic Drugs, Janus Kinase Inhibitors, Nonsteroidal Anti-Inflammatory Drugs, and Phosphodiesterase Inhibitors, with each class posing different demands for clinical evidence, manufacturing complexity, and post-marketing safety surveillance. Based on Mechanism Of Action, therapies target Cyclooxygenase pathways, Interleukin signaling, Janus Kinase cascades, Phosphodiesterase enzymes, and Tumor Necrosis Factor, and the mechanistic diversity necessitates tailored biomarker strategies and differentiated clinical endpoints.

Based on Route Of Administration, therapeutic delivery choices include Oral, Parenteral, and Topical formats, where parenteral administration divides further into Intramuscular, Intravenous, and Subcutaneous approaches and topical treatments are delivered via Creams, Gels, and Ointments; these delivery distinctions influence adherence profiles, healthcare utilization patterns, and the complexity of manufacturing and distribution. Based on Distribution Channel, therapies move through Hospital Pharmacy networks, Online Pharmacy platforms, and Retail Pharmacy outlets, and each channel carries different requirements for cold-chain, patient support, and reimbursement interactions. Based on Indication, clinical targets include Asthma And Pulmonary Diseases, Gout, Inflammatory Bowel Disease, Osteoarthritis, Psoriasis, and Rheumatoid Arthritis, with Inflammatory Bowel Disease further categorized into Crohn's Disease and Ulcerative Colitis; indication-specific natural history affects trial design, responder definitions, and long-term safety monitoring. Based on End User, settings span Clinic, Home Care, Hospital, and Specialty Center, with each care environment influencing point-of-care delivery, patient education needs, and support service integration.

Taken together, this segmentation framework highlights that therapeutic success is contingent on aligning molecule attributes with the operational realities of manufacturing, channels, and clinical care settings. Strategic planners should consider how a therapy's class and mechanism guide evidence generation, how administration route shapes patient experience and adherence, and how distribution and end-user dynamics will affect access, uptake, and lifecycle management. In practice, cross-functional alignment between R&D, commercial, manufacturing, and market access teams is essential to translate segment-specific requirements into executable development and launch plans.

Region-specific strategic considerations that reconcile regulatory diversity, reimbursement paradigms, and infrastructure realities across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics exert a strong influence on regulatory interactions, reimbursement pathways, and commercial execution, with each geography presenting distinctive clinical paradigms and operational priorities. In the Americas, healthcare systems vary from highly privatized to public payer-dominated models, driving heterogeneity in formulary decisions, access timelines, and patient support program requirements. Clinical practice patterns and guideline adoption in this region influence comparative effectiveness expectations and the evidence standards that payers and providers demand.

In Europe, Middle East & Africa, regulatory harmonization efforts coexist with significant variation in reimbursement capacity and health technology assessment methodologies. Manufacturers must navigate diverse pricing environments, local guideline adoption, and varying degrees of infrastructure for specialty care, which affects launch sequencing and patient access strategies. Capacity constraints in certain markets can also influence distribution and cold-chain investments.

In Asia-Pacific, rapid adoption of innovative therapies is often balanced against affordability pressures and evolving regulatory frameworks that can accelerate approval for therapies addressing high unmet need. Local manufacturing partnerships and regional clinical development programs are frequently used to support access and meet regulatory expectations. Across all regions, cross-border supply chain resilience, pharmacovigilance harmonization, and culturally tailored patient support models are critical for ensuring sustainable access and maximizing clinical impact.

How leading firms are combining scientific differentiation, strategic partnerships, and lifecycle tactics to optimize therapeutic pipelines and demonstrate payer-aligned value

Competitive behavior among leading companies reflects a mix of scientific differentiation, strategic partnerships, and portfolio optimization. Industry players are prioritizing targeted therapies with clear mechanistic rationales and have been investing in biologics and small molecules that offer improved safety and specificity compared with older broad-spectrum agents. Cross-sector collaborations and licensing arrangements are widespread as firms seek to complement internal capabilities with external innovation, accelerate time to clinic, and de-risk late-stage development.

Manufacturers are also placing an increased emphasis on life-cycle management tactics, including reformulations, novel delivery systems, and indication expansion strategies to extend therapeutic relevance. In parallel, companies are investing in real-world evidence generation, patient engagement platforms, and outcomes-based contracting models to demonstrate value to payers and health systems. Organizationally, there is a trend toward integrated teams that combine clinical development, market access, and commercial functions to ensure that evidence packages align with payer expectations and provider needs.

These competitive dynamics underscore the importance of agility, data-driven decision-making, and strategic partnering. Enterprises that can efficiently translate mechanistic insight into differentiated products, while simultaneously building robust evidence generation and access strategies, are positioned to navigate both clinical and commercial complexities.

Practical and prioritized actions for executives to align R&D, manufacturing, market access, and commercial teams to ensure resilient launches and sustained therapeutic adoption

Industry leaders should adopt an integrated approach that aligns early-stage scientific choices with downstream access and commercial requirements. Initiatives should include embedding payer and health economics input at the earliest program design stages to ensure that trial endpoints and health outcome measures will be credible to reimbursement stakeholders. Simultaneously, investments in manufacturing flexibility and geographic diversification will safeguard supply continuity and reduce exposure to trade disruptions.

Commercial plans must prioritize patient-centric delivery models and digital support mechanisms that improve adherence and enable remote monitoring of therapeutic response. Strategic partnerships with clinical networks, specialty pharmacies, and technology vendors can accelerate patient access and reduce the burden on traditional distribution channels. Moreover, life-cycle management should be treated as a continuous process that encompasses reformulation, delivery innovation, and indication sequencing to sustain clinical relevance.

Finally, organizations should institutionalize agile governance frameworks that facilitate cross-functional decision-making, rapid evidence integration, and scenario-based planning. These practical steps will enable companies to translate clinical innovation into durable commercial success while maintaining alignment with payer expectations and patient needs.

Transparent methodology combining expert interviews, targeted secondary review, and cross-sectional analytic techniques to validate clinical, regulatory, and operational insights

The research underpinning this executive summary synthesizes primary qualitative interviews, targeted secondary literature review, and structured analysis of regulatory and policy changes. Key informant interviews included clinical thought leaders, supply chain executives, market access specialists, and therapeutic area experts to capture multi-stakeholder perspectives. Secondary sources encompassed peer-reviewed clinical literature, regulatory guidance documents, and technical white papers that contextualize mechanism-specific evidence and delivery considerations.

Analytical methods combined thematic synthesis with cross-sectional mapping of segmentation attributes to identify where clinical innovation intersects with operational constraints. Evidence validation steps included triangulation of interview findings with published clinical data and supply chain disclosures. Limitations and uncertainties are acknowledged, and sensitivity to evolving regulatory and trade dynamics was incorporated through scenario-based analysis. The methodology emphasizes transparency in source attribution and reproducibility of analytic choices to support informed decision-making.

Conclusion synthesizing how therapeutic innovation, evidence alignment, and operational execution collectively determine long-term success and patient impact in inflammatory diseases

In summary, the anti-inflammatory therapeutics landscape is being reshaped by precise mechanistic targeting, adaptive regulatory expectations, and heightened demands for demonstrable real-world value. These forces create both opportunities and responsibilities for developers, payers, and providers to collaborate on evidence generation, supply chain resilience, and patient-centered care models. Therapeutic differentiation increasingly requires alignment across molecule design, delivery format, and market access strategies to ensure uptake and sustainable patient benefit.

Moving forward, stakeholders who integrate clinical evidence with pragmatic operational planning will be best positioned to deliver meaningful outcomes while navigating commercial complexity. Sustained success depends not only on scientific innovation but also on the ability to orchestrate manufacturing, regulatory, and payer engagements in a coordinated fashion. The conclusion reinforces that strategic foresight, cross-functional execution, and a relentless focus on patient outcomes are the foundational elements for enduring impact in the anti-inflammatory domain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-Inflammatory Therapeutics Market, by Therapeutic Class

  • 8.1. Biologics
  • 8.2. Corticosteroids
  • 8.3. Disease Modifying Antirheumatic Drugs
  • 8.4. Janus Kinase Inhibitors
  • 8.5. Nonsteroidal Anti-Inflammatory Drugs
  • 8.6. Phosphodiesterase Inhibitors

9. Anti-Inflammatory Therapeutics Market, by Mechanism Of Action

  • 9.1. Cyclooxygenase Inhibitors
  • 9.2. Interleukin Inhibitors
  • 9.3. Janus Kinase Inhibitors
  • 9.4. Phosphodiesterase Inhibitors
  • 9.5. Tumor Necrosis Factor Inhibitors

10. Anti-Inflammatory Therapeutics Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Parenteral
    • 10.2.1. Intramuscular
    • 10.2.2. Intravenous
    • 10.2.3. Subcutaneous
  • 10.3. Topical
    • 10.3.1. Creams
    • 10.3.2. Gels
    • 10.3.3. Ointments

11. Anti-Inflammatory Therapeutics Market, by Indication

  • 11.1. Asthma And Pulmonary Diseases
  • 11.2. Gout
  • 11.3. Inflammatory Bowel Disease
    • 11.3.1. Crohn's Disease
    • 11.3.2. Ulcerative Colitis
  • 11.4. Osteoarthritis
  • 11.5. Psoriasis
  • 11.6. Rheumatoid Arthritis

12. Anti-Inflammatory Therapeutics Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Anti-Inflammatory Therapeutics Market, by End User

  • 13.1. Clinic
  • 13.2. Home Care
  • 13.3. Hospital
  • 13.4. Specialty Center

14. Anti-Inflammatory Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Anti-Inflammatory Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Anti-Inflammatory Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Anti-Inflammatory Therapeutics Market

18. China Anti-Inflammatory Therapeutics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Amgen Inc.
  • 19.7. AstraZeneca PLC, Amgen Inc.
  • 19.8. Bioventus
  • 19.9. Bristol-Myers Squibb Company
  • 19.10. Eli Lilly and Company
  • 19.11. F. Hoffmann-La Roche Ltd
  • 19.12. Ferring Pharmaceuticals
  • 19.13. Flexion Therapeutics, Inc
  • 19.14. GlaxoSmithKline
  • 19.15. Johnson & Johnson
  • 19.16. La Roche AG
  • 19.17. Merck & CO., Inc.
  • 19.18. Novartis AG
  • 19.19. Pfizer Inc.
  • 19.20. Sanofi S.A.
  • 19.21. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISEASE MODIFYING ANTIRHEUMATIC DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISEASE MODIFYING ANTIRHEUMATIC DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISEASE MODIFYING ANTIRHEUMATIC DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CYCLOOXYGENASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CYCLOOXYGENASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CYCLOOXYGENASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ASTHMA AND PULMONARY DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ASTHMA AND PULMONARY DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ASTHMA AND PULMONARY DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GOUT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GOUT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GOUT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. GCC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. GCC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 211. GCC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. GCC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 213. GCC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 214. GCC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 215. GCC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 216. GCC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. GCC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. G7 ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. G7 ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 240. G7 ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 241. G7 ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. G7 ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 243. G7 ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 244. G7 ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 245. G7 ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 246. G7 ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. G7 ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. NATO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. NATO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 250. NATO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 251. NATO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 252. NATO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 253. NATO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 254. NATO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 255. NATO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 256. NATO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. NATO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)